Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy

被引：0

作者：

Kenichi Inoue

Norikazu Masuda

Hiroji Iwata

Masato Takahashi

Yoshinori Ito

Yasuo Miyoshi

Takahiro Nakayama

Hirofumi Mukai

Jan-Stefan van der Walt

Joji Mori

Sachi Sakaguchi

Tsutomu Kawaguchi

Yoshinori Tanizawa

Antonio Llombart-Cussac

George W. Sledge

Masakazu Toi

机构：

[1] Saitama Cancer Center,Department of Breast Oncology

[2] National Hospital Organization,Breast Cancer Unit, Breast Surgery, Graduate School of Medicine

[3] Osaka National Hospital,undefined

[4] Aichi Cancer Center Hospital,undefined

[5] National Hospital Organization Hokkaido Cancer Center,undefined

[6] The Cancer Institute Hospital,undefined

[7] Hyogo College of Medicine,undefined

[8] Osaka International Cancer Institute,undefined

[9] National Cancer Center Hospital East,undefined

[10] Eli Lilly and Company,undefined

[11] Eli Lilly Japan K.K.,undefined

[12] Hospital Arnau de Vilanova,undefined

[13] SOLTI Breast Cancer Research Group,undefined

[14] Stanford University School of Medicine,undefined

[15] Kyoto University Hospital,undefined

[16] Kyoto University,undefined

来源：

Breast Cancer | 2021年 / 28卷

关键词：

Abemaciclib; Breast cancer; Cyclin-dependent kinase 4 and 6 inhibitor;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1038 / 1050

页数：12

共 50 条

[1] Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy
Inoue, Kenichi
Masuda, Norikazu
Iwata, Hiroji
Takahashi, Masato
Ito, Yoshinori
Miyoshi, Yasuo
Nakayama, Takahiro
Mukai, Hirofumi
van der Walt, Jan-Stefan
Mori, Joji
Sakaguchi, Sachi
Kawaguchi, Tsutomu
Tanizawa, Yoshinori
Llombart-Cussac, Antonio
Sledge, George W., Jr.
Toi, Masakazu
BREAST CANCER, 2021, 28 (05) : 1038 - 1050
[2] Final overall survival analysis of MONARCH 2: a Phase 3 trial of abemaciclib plus fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative Advanced Breast Cancer
Grischke, E. M.
Llombart-Cussac, A.
Toi, M.
Neven, P.
Sohn, J.
Inoue, K.
Pivot, X.
Okera, M.
Masuda, N.
Kaufman, P. A.
Koh, H.
Conte, P.
Andre, V
Bian, F.
Shahir, A.
van Hal, G.
Sledge Jr, G. W.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 30 - 30
[3] Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
Takahashi, Masato
Tokunaga, Eriko
Mori, Joji
Tanizawa, Yoshinori
Van der Walt, Jan-Stefan
Kawaguchi, Tsutomu
Goetz, Matthew P.
Toi, Masakazu
BREAST CANCER, 2022, 29 (01) : 174 - 184
[4] Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
Masato Takahashi
Eriko Tokunaga
Joji Mori
Yoshinori Tanizawa
Jan-Stefan van der Walt
Tsutomu Kawaguchi
Matthew P. Goetz
Masakazu Toi
Breast Cancer, 2022, 29 : 174 - 184
[5] Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial
Neven, Patrick
Rugo, Hope S.
Tolaney, Sara M.
Iwata, Hiroji
Toi, Masakazu
Goetz, Matthew P.
Kaufman, Peter A.
Lu, Yi
Haddad, Nadine
Hurt, Karla C.
Sledge, George W., Jr.
BREAST CANCER RESEARCH, 2021, 23 (01)
[6] Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial
Patrick Neven
Hope S. Rugo
Sara M. Tolaney
Hiroji Iwata
Masakazu Toi
Matthew P. Goetz
Peter A. Kaufman
Yi Lu
Nadine Haddad
Karla C. Hurt
George W. Sledge
Breast Cancer Research, 23
[7] Management of abemaciclib associated diarrhea in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Analysis of the MONARCH plus study
Jiang, Zefei
Hu, Xichun
Zhang, Qingyuan
Sun, Tao
Yin, Yongmei
Li, Huiping
Yan, Min
Tong, Zhongsheng
Oppermann, Christina Pimentel
Liu, Yunpeng
Costa, Romulo
Li, Man
Chen, Xi
Cheng, Ying
Ouyang, Quchang
Liao, Ning
Wang, Xiaojia
Wu, Xinhong
Feng, Jifeng
Hegg, Roberto
Setty, Govindbabu Kanaka
Agarwal, Amit
Bajpai, Jyoti
Cheng, Jing
Girotto, Gustavo
Goswami, Chanchal
Hu, Wenjing
Huang, Jian
Portugal, M. A. Coccia
Yang, Jin
Zheng, Rongsheng
Franke, Fabio Andre
Liu, Qiang
Liu, Yunjiang
Lu, Yongkui
Souza, Cristiano
Yu, Shiying
Kilara, Nalini
Panchal, Harsha
Singh, Ashish
Nag, Shona
Liu, Jian
Rapoport, Bernardo
Tabane, Neonyana Keorapetse Rebecca
Wang, Hongxia
Wang, Ning
Han, Rubing
Zhang, Wanli
CANCER RESEARCH, 2021, 81 (04)
[8] Fulvestrant in the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: A review
Li, Junjie
Wang, Zhonghua
Shao, Zhimin
CANCER MEDICINE, 2019, 8 (05): : 1943 - 1957
[9] Abemaciclib plus fulvestrant for the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer with cystic brain metastases: A case report and literature review
Chu, Zhaohui
FRONTIERS IN ONCOLOGY, 2022, 12
[10] Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials
Goetz, Matthew P.
Okera, Meena
Wildiers, Hans
Campone, Mario
Grischke, Eva-Maria
Manso, Luis
Andre, Valerie A. M.
Chouaki, Nadia
San Antonio, Belen
Toi, Masakazu
Sledge, George W.
BREAST CANCER RESEARCH AND TREATMENT, 2021, 186 (02) : 417 - 428

← 1 2 3 4 5 →